Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Clinical Features, Diagnosis, Management, and Long-Term Follow-Up Abstract #981

Introduction: There are a few large series of patients with parathyroid hormone (PTH)-related protein (PTHrP) secreting neuroendocrine tumors (NETs) causing severe hypercalcemia.
Aim(s): To analyze the clinical, biochemical, radiological features, response to therapy and survival of patients with PTHrP-secreting NETs.
Materials and methods: Ten patients with PTHrP-secreting GEP-NETs treated between 1986-2013. MEN1 was excluded. Patients were assessed for progressive disease (PD) and response to therapy of hypercalcemia with three parameters: (1) radiological documentation of PD, (2) progression of clinical symptoms, (3) worsening of biochemical markers. Overall survival (OS) was analyzed using a KM curve.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Drs Kimberly Kamp
Keywords: PTH, PTHrP, net, hypercalcemia

To read results and conclusion, please login ...

Further abstracts you may be interested in

#810 Pancreatic Neuroendocrine Tumor Presenting in Pregnancy with Severe Hypercalcemia
Introduction: Malignant hypercalcemia secondary to pancreatic neuroendocrine tumor (pNET) is a rare occurrence with no standard management. We report a challenging case of pNET presenting during pregnancy and complicated by severe hypercalcemia.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Rita E Assi
#723 The Calcium Metabolism Disturbances 40 Patients with Neuroendocrine Tumors: A Cross-Sectional Study
Introduction: Bone diseases associated with NET are due to genetic background, NET evolution, or they are incidental.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Catalina Poiana
Authors: Poiana C, Carsote M, Dusceac R, Muler M, ...
Keywords: PTH, calcium
#2212 A Rare Case of Paraneoplastic Hypercalcemia Secondary to a Neuroendocrine Pancreatic Tumour (pNET).
Introduction: Paraneoplastic hypercalcemia (HC) is a well-described affection in literature. It can relay on several mechanisms among with bone osteolysis, Parathormone (PTH) related peptide (rp) production, primary hyperparathyroidism, and Calcitriol (CT) secretion. CT secretion-mediated HC is more frequently observed among lymphomas and has only been once reported in pNET.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Dr. Aïmen Belaïd
Authors: Belaïd A, Dhenin A, Jopart P, Seront E, ...
#186 Occurrence of Other Primary Malignancies in Patients with Endocrine Tumors of the Digestive Tract and Pancreas
Introduction: Endocrine tumors of the digestive tract and pancreas (GEP-NET) are often considered to be associated with other primary malignancies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kimberly Kamp
#712 A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT
Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp
Authors: Kamp K, Feelders R, De Herder W, ...